Christine E. Horak

35.7k total citations · 3 hit papers
72 papers, 5.0k citations indexed

About

Christine E. Horak is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Christine E. Horak has authored 72 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 31 papers in Molecular Biology and 15 papers in Immunology. Recurrent topics in Christine E. Horak's work include Cancer Immunotherapy and Biomarkers (35 papers), CAR-T cell therapy research (25 papers) and Immunotherapy and Immune Responses (15 papers). Christine E. Horak is often cited by papers focused on Cancer Immunotherapy and Biomarkers (35 papers), CAR-T cell therapy research (25 papers) and Immunotherapy and Immune Responses (15 papers). Christine E. Horak collaborates with scholars based in United States, France and Germany. Christine E. Horak's co-authors include M Snyder, David Botstein, Vishwanath R. Iyer, Charles Scafe, Patrick O. Brown, Patricia S. Steeg, Jeffrey S. Weber, Jedd D. Wolchok, F. Stephen Hodi and Mark Gerstein and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nature Genetics.

In The Last Decade

Christine E. Horak

72 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genomic binding sites of the yeast cell-cycle transcription factors SBF and MBF

2001 841 citations Vishwanath R. Iyer, Christine E. Horak et al. Nature profile →
Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma

2013 440 citations Jeffrey S. Weber, Christine E. Horak et al. Journal of Clinical Oncology profile →
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

2018 408 citations Scott J. Rodig, Daniel Gusenleitner et al. Science Translational Medicine profile →

Peers

Christine E. Horak

ONCOL

IMMUN

PRM

Uwe Trefzer Germany

Shan Zha United States

Helen Rizos Australia

Anne W. Hamburger United States

David J. Bearss United States

Huw D. Thomas United Kingdom

Michael Hölzel Germany

Timothy F. Burns United States

Sorena Nadaf United States

Hannah Farmer United Kingdom

Uwe Trefzer Germany

Christine E. Horak

2.7k ×1.0

ONCOL

2.8k ×1.1

1.1k ×0.8

IMMUN

385 ×0.6

PRM

341 ×0.8

Citations per year, relative to Christine E. Horak Christine E. Horak (= 1×) peers Uwe Trefzer

Countries citing papers authored by Christine E. Horak

Since Specialization

Citations

This map shows the geographic impact of Christine E. Horak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine E. Horak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine E. Horak more than expected).

Fields of papers citing papers by Christine E. Horak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christine E. Horak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine E. Horak. The network helps show where Christine E. Horak may publish in the future.

Co-authorship network of co-authors of Christine E. Horak

This figure shows the co-authorship network connecting the top 25 collaborators of Christine E. Horak. A scholar is included among the top collaborators of Christine E. Horak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christine E. Horak. Christine E. Horak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yusko, Erik, Marissa Vignali, Richard K. Wilson, et al.. (2019). Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma. Cancer Immunology Research. 7(3). 458–465. 38 indexed citations

Rodig, Scott J., Daniel Gusenleitner, Donald Jackson, et al.. (2018). MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Science Translational Medicine. 10(450). 408 indexed citations breakdown →

Galsky, Matthew D., Abdel Saci, Péter M. Szabó, et al.. (2017). Impact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: Exploratory analysis of the phase ii checkmate 275 study. Annals of Oncology. 28. v296–v297. 49 indexed citations

Miao, Diana, Claire A. Margolis, Dylan J. Martini, et al.. (2017). Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma.. Journal of Clinical Oncology. 35(15_suppl). 3016–3016. 3 indexed citations

Long, Georgina V., James Larkin, Paolo A. Ascierto, et al.. (2016). PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis. Annals of Oncology. 27. vi381–vi381. 18 indexed citations

Weber, Jeffrey S., Christine E. Horak, F. Stephen Hodi, et al.. (2016). Baseline tumor T cell receptor (TcR) sequencing analysis and neo antigen load is associated with benefit in melanoma patients receiving sequential nivolumab and ipilimumab. Annals of Oncology. 27. vi359–vi359. 9 indexed citations

Festino, Lucia, Gerardo Botti, Paul Lorigan, et al.. (2016). Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. Drugs. 76(9). 925–945. 120 indexed citations

Wolchok, Jedd D., Vanna Chiarion‐Sileni, René González, et al.. (2015). Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).. Journal of Clinical Oncology. 33(15_suppl). LBA1–LBA1. 7 indexed citations

Wolchok, Jedd D., Vanna Chiarion‐Sileni, René González, et al.. (2015). CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL). Annals of Oncology. 26. vi28–vi28. 6 indexed citations

10.

Horak, Christine E., Lajos Pusztai, Guan Xing, et al.. (2013). Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer. Clinical Cancer Research. 19(6). 1587–1595. 83 indexed citations

11.

Denne, Jonathan, Luping Zhao, Christine E. Horak, et al.. (2013). Comparison of KRAS Genotype: Therascreen Assay vs. LNA-Mediated qPCR Clamping Assay. Clinical Colorectal Cancer. 12(3). 195–203.e2. 5 indexed citations

12.

Sosman, Jeffrey A., Salvador Martín‐Algarra, Jedd D. Wolchok, et al.. (2013). An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL).. Journal of Clinical Oncology. 31(15_suppl). TPS3114–TPS3114. 3 indexed citations

13.

Collins, Joshua W., Joji Nakayama, Christine E. Horak, et al.. (2012). Effect of Inhibition of the Lysophosphatidic Acid Receptor 1 on Metastasis and Metastatic Dormancy in Breast Cancer. JNCI Journal of the National Cancer Institute. 104(17). 1306–1319. 108 indexed citations

14.

Lee, Jong‐Heun, Christine E. Horak, Chand Khanna, et al.. (2008). Alterations in Gemin5 Expression Contribute to Alternative mRNA Splicing Patterns and Tumor Cell Motility. Cancer Research. 68(3). 639–644. 41 indexed citations

15.

Horak, Christine E., Jong‐Heun Lee, Abdel Elkahloun, et al.. (2007). Nm23-H1 Suppresses Tumor Cell Motility by Down-regulating the Lysophosphatidic Acid Receptor EDG2. Cancer Research. 67(15). 7238–7246. 99 indexed citations

16.

Horak, Christine E., Arnulfo Mendoza, Eleazar Vega-Valle, et al.. (2007). Nm23-H1 Suppresses Metastasis by Inhibiting Expression of the Lysophosphatidic Acid Receptor EDG2. Cancer Research. 67(24). 11751–11759. 73 indexed citations

17.

Horak, Christine E., Milind Mahajan, Nicholas M. Luscombe, et al.. (2002). GATA-1 binding sites mapped in the β-globin locus by using mammalian chIp-chip analysis. Proceedings of the National Academy of Sciences. 99(5). 2924–2929. 136 indexed citations

18.

Horak, Christine E. & M Snyder. (2002). ChIP-chip: A genomic approach for identifying transcription factor binding sites. Methods in enzymology on CD-ROM/Methods in enzymology. 350. 469–483. 133 indexed citations

19.

Horak, Christine E., Nicholas M. Luscombe, Jiang Qian, et al.. (2002). Complex transcriptional circuitry at the G1/S transition in Saccharomyces cerevisiae. Genes & Development. 16(23). 3017–3033. 212 indexed citations

20.

Iyer, Vishwanath R., Christine E. Horak, Charles Scafe, et al.. (2001). Genomic binding sites of the yeast cell-cycle transcription factors SBF and MBF. Nature. 409(6819). 533–538. 841 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact